nightriders
New member
חיסון לשעלת
מאמר שהתפרסם לא מזמן ב BMJ.
There is a growing feeling among experts that modern acellular
vaccines against Bordetella pertussis are not as durable as the
old whole cell ones. A case-control study of children from
California seems to support this theory, with odds of infection
rising and vaccine efficacy falling with each year since
completion of the vaccination schedule. Estimated efficacy of
five doses of the acellular vaccine fell from 98.1% (95% CI
96.1% to 99.1%) in the 12 months after the last dose to 71.2%
(45.8% to 84.8%) after five years.
The authors compared the vaccination histories of 682 people
reported to have whooping cough with 2016 uninfected controls.
All were recruited in 2010, during the biggest outbreak for 60
years, in which 10 infants died. This study and others were
launched in response to particularly high rates of whooping
cough among preadolescents, despite high coverage of the
recommended DTaP (diphtheria, tetanus, and acellular pertussis)
vaccine.
The new analyses add to other circumstantial evidence from
California and elsewhere that current vaccine strategies aren’t
working for long enough to protect vulnerable groups of older
children, says a linked editorial (p 2149). Whooping cough can
be serious for these children and deadly for any young
unvaccinated infants who they come into contact with. Better
vaccines might be needed in the long run. Meanwhile, public
health authorities should consider redesigning schedules to make
smarter use of the vaccine that we have, which works
considerably better than nothing.
הדיווח הזה מתייחס למעשה למחקר שפורסם ב JAMA
לפני שנתיים, בו בוחנים את יעילות חיסון השעלת , ורואים במחקר מקרה ביקורת כי השלמת תוכנית החיסון נותנת הגנה אך היא הולכת ויורדת ככל שמתרחקים מהמנה האחרונה.
קישור לתקציר למי שמעוניין
מאמר שהתפרסם לא מזמן ב BMJ.
There is a growing feeling among experts that modern acellular
vaccines against Bordetella pertussis are not as durable as the
old whole cell ones. A case-control study of children from
California seems to support this theory, with odds of infection
rising and vaccine efficacy falling with each year since
completion of the vaccination schedule. Estimated efficacy of
five doses of the acellular vaccine fell from 98.1% (95% CI
96.1% to 99.1%) in the 12 months after the last dose to 71.2%
(45.8% to 84.8%) after five years.
The authors compared the vaccination histories of 682 people
reported to have whooping cough with 2016 uninfected controls.
All were recruited in 2010, during the biggest outbreak for 60
years, in which 10 infants died. This study and others were
launched in response to particularly high rates of whooping
cough among preadolescents, despite high coverage of the
recommended DTaP (diphtheria, tetanus, and acellular pertussis)
vaccine.
The new analyses add to other circumstantial evidence from
California and elsewhere that current vaccine strategies aren’t
working for long enough to protect vulnerable groups of older
children, says a linked editorial (p 2149). Whooping cough can
be serious for these children and deadly for any young
unvaccinated infants who they come into contact with. Better
vaccines might be needed in the long run. Meanwhile, public
health authorities should consider redesigning schedules to make
smarter use of the vaccine that we have, which works
considerably better than nothing.
הדיווח הזה מתייחס למעשה למחקר שפורסם ב JAMA
לפני שנתיים, בו בוחנים את יעילות חיסון השעלת , ורואים במחקר מקרה ביקורת כי השלמת תוכנית החיסון נותנת הגנה אך היא הולכת ויורדת ככל שמתרחקים מהמנה האחרונה.
קישור לתקציר למי שמעוניין